Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Consensus Rating of “Moderate Buy” from Analysts

Sutro Biopharma, Inc. (NASDAQ:STRO) has received a consensus rating of “Moderate Buy” from the six analysts that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1 year target price among analysts that have covered the stock in the last year is $16.00.

Several analysts have issued reports on the stock. Wedbush cut their target price on shares of Sutro Biopharma from $20.00 to $12.00 and set an “outperform” rating on the stock in a research note on Friday, August 11th. HC Wainwright restated a “buy” rating and set a $16.00 price objective on shares of Sutro Biopharma in a research report on Friday, August 11th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $17.00 target price on shares of Sutro Biopharma in a report on Monday, August 14th.

Insider Transactions at Sutro Biopharma

In related news, insider Brunilda Shtylla sold 15,428 shares of the stock in a transaction that occurred on Monday, August 28th. The stock was sold at an average price of $4.71, for a total value of $72,665.88. The transaction was disclosed in a filing with the SEC, which is available at this link. Company insiders own 6.90% of the company’s stock.

Institutional Investors Weigh In On Sutro Biopharma

A number of large investors have recently bought and sold shares of the business. Swiss National Bank lifted its position in shares of Sutro Biopharma by 8.2% in the first quarter. Swiss National Bank now owns 76,600 shares of the company’s stock worth $630,000 after buying an additional 5,800 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in Sutro Biopharma by 204.1% in the 1st quarter. JPMorgan Chase & Co. now owns 170,766 shares of the company’s stock worth $1,403,000 after purchasing an additional 114,610 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in Sutro Biopharma during the first quarter worth approximately $1,233,000. MetLife Investment Management LLC grew its holdings in Sutro Biopharma by 55.3% during the first quarter. MetLife Investment Management LLC now owns 25,503 shares of the company’s stock valued at $210,000 after purchasing an additional 9,080 shares during the last quarter. Finally, BlackRock Inc. raised its position in shares of Sutro Biopharma by 0.8% in the first quarter. BlackRock Inc. now owns 3,728,829 shares of the company’s stock valued at $30,650,000 after purchasing an additional 28,786 shares during the period. 89.40% of the stock is currently owned by institutional investors.

Sutro Biopharma Trading Down 5.3 %

Shares of STRO opened at $4.50 on Tuesday. The business’s 50-day moving average price is $4.58 and its 200 day moving average price is $4.93. The stock has a market capitalization of $272.25 million, a P/E ratio of -1.82 and a beta of 0.86. Sutro Biopharma has a 1-year low of $3.99 and a 1-year high of $8.72.

Sutro Biopharma (NASDAQ:STRO) last released its earnings results on Thursday, August 10th. The company reported ($0.64) earnings per share for the quarter, topping the consensus estimate of ($0.73) by $0.09. Sutro Biopharma had a negative net margin of 250.87% and a negative return on equity of 69.71%. The business had revenue of $10.41 million for the quarter, compared to the consensus estimate of $10.45 million. On average, research analysts predict that Sutro Biopharma will post -2.95 earnings per share for the current year.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. It develops site-specific and novel-format antibody drug conjugates (ADC) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. The company's product candidates include STRO-001, an ADC directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials.